CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Key Takeaways Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration.The drugmaker said the twice-daily pill, Journavx, is the first such treatment to ...
This category includes pain that can pop up due to injuries, following surgeries, or as a symptom of an illness. What makes Journavx different is its unique way of working; instead of acting on the ...
Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.